LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

The past, present, and future of HER2 (ERBB2) in cancer: Approaches to molecular testing and an evolving role in targeted therapy

Photo by nci from unsplash

Jaclyn F. Hechtman is an assistant member of pathology at Memorial Sloan Kettering Cancer Center in New York City. She practices molecular and gastrointestinal pathology and also participates in assay… Click to show full abstract

Jaclyn F. Hechtman is an assistant member of pathology at Memorial Sloan Kettering Cancer Center in New York City. She practices molecular and gastrointestinal pathology and also participates in assay validation for targetable molecular alterations and serves as director of clinical biomarker development within the Early Drug Development Service. Her research interests include microsatellite instability, kinase fusions, and ERBB2 alterations with respect to molecular diagnostics and translational and clinical oncology.

Keywords: pathology; her2 erbb2; future her2; cancer; present future; past present

Journal Title: Cancer Cytopathology
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.